Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors (Q34651534)

3 August 2017

1 reference

title

Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors (English)

1 reference

3 August 2017

Desirée Hao

1

1 reference

3 August 2017

Eric K Rowinsky

series ordinal

2

1 reference

3 August 2017

publication date

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

20

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

387-404

1 reference

Growth factors and cancer

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Oncogenes and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

The protein kinase family: conserved features and deduced phylogeny of the catalytic domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Signal transduction by receptors with tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Cytokine signaling through nonreceptor protein tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

A point mutation in the neu oncogene mimics ligand induction of receptor aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

The epidermal growth factor receptor as a target for therapy in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Tyrosine protein kinase inhibition and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Tyrosine kinase inhibition: an approach to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Protein kinase inhibitors: the tyrosine-specific protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Tyrosine kinase activity is essential for the association of phospholipase C-gamma with the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Tyrphostins. II. Heterocyclic and .alpha.-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Tyrphostins. 3. Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-S-aryltyrphostins

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Antisense oligonucleotides to the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

All ras proteins are polyisoprenylated but only some are palmitoylated

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

The Ras signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Activation of the cellular proto-oncogene product p21Ras by addition of a myristylation signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

The potential of farnesyltransferase inhibitors as cancer chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120001184

21 January 2018

Identifiers

DOI

10.1081/CNV-120001184

1 reference

3 August 2017

1 reference